en · de · es · fr · pt
aod-9604-notes.peptides3081.com › Topic › Background And Research Context — 2026 Update

Background And Research Context — 2026 Update

By Editorial Desk · published 2026-04-30 · last reviewed 2026-06-22 · Topic

A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-06-22. Anything still debated is marked as such rather than presented as settled.

Background And Research Context

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

Mechanism and Regulatory Status

Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.

Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.

Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.

Aod-9604 at a glance

PropertyValueNotes
Common synonymhGH fragment 176-191Refers to the C-terminal segment
AppearanceWhite to off-white powderTypically supplied lyophilized
SolubilitySoluble in water and aqueous buffersConfirm with technical data
Typical storage temperature-20 °C for dry powderProtect from moisture and light
Common analytical methodRP-HPLC with UV detectionOften paired with mass spectrometry

Regulatory and Analytical Context

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Related pages on this site

Mechanism And Metabolic Effects

Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.

Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.

A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.

Background from the literature

It is possible for an entire large sand pile to reach a point where it is stable, but the addition of a single grain causes large parts of it to collapse. The avalanche is a well-known problem with large piles of snow and ice crystals on steep slopes. In dry conditions, snow slopes act similarly to sandpiles. An entire mountainside of snow can suddenly slide due to the presence of a skier, or even a loud noise or vibration.

==== Formation of metastable species ==== As the gas (M) enters the ion source, an electric potential in the range of +1 to +5 kV is applied to generate a glow discharge. The glow discharge plasma contains short-lived energetic species including electrons, ions, and excimers. Ion/electron recombination leads to the formation of long-lived excited-state neutral atoms or molecules (metastable species, M*) in the flowing afterglow region. The DART gas can be heated from room temperature (RT) to 550 °C to facilitate desorption of analyte molecules. Heating is optional but may be necessary depending on the surface or chemical being analyzed. The heated stream of gaseous metastable species passes through a porous exit electrode that is biased to a positive or negative potential in the range 0 to 530V. When biased to a positive potential, the exit electrode acts to remove electrons and negative ions formed by Penning ionization from the gas stream to prevent ion/electron recombination and ion loss. If the exit electrode is biased to a negative potential, electrons can be generated directly from the electrode material by surface Penning ionization. An insulator cap at the terminal end of the ion source protects the operator from harm.

== Annual themes == 2019 - Diversity; diversity of applications, people, careers, locations, technology, science, engineered solutions, and innovation. 2020 - The Cold Chain; role of the Cold chain sector in food safety and security, and human health. 2021 - Careers; aimed at students and young professionals. 2022 - Cooling Matters; raise awareness of the benefits and impacts of cooling, and technology solutions for sustainability. 2023 - Next Generation Cooling; highlighting innovative technologies that improve energy efficiency and promote sustainable practices going into the future. 2024 - Temperature Matters; highlighting the significance of temperature control in daily life.

== Consumer acceptance == Historically, consumers paid little attention to food technologies. Nowadays, the food production chain is long and complicated and food technologies are diverse. Consequently, consumers are uncertain about the determinants of food quality and find it difficult to understand them. Now, acceptance of food products very often depends on perceived benefits and risks associated with food. Popular views of food processing technologies matter. Especially innovative food processing technologies often are perceived as risky by consumers. Acceptance of the different food technologies varies. While pasteurization is well recognized and accepted, high pressure treatment and even microwaves often are perceived as risky. Studies by the Hightech Europe project found that traditional technologies were well accepted in contrast to innovative technologies. Consumers form their attitude towards innovative food technologies through three main mechanisms: First, through knowledge or beliefs about risks and benefits correlated with the technology; second, through attitudes based on their own experience; and third, through application of higher order values and beliefs. A number of scholars consider the risk-benefit trade-off as one of the main determinants of consumer acceptance, although some researchers place more emphasis on the role of benefit perception (rather than risk) in consumer acceptance.

Sources: en.wikipedia.org

Reference notes

peripheral membrane protein Also extrinsic membrane protein. Any of a class of membrane proteins which attach only temporarily to the cell membrane, either by penetrating the lipid bilayer or by attaching to other proteins which are permanently embedded within the membrane. The ability to reversibly interact with membranes makes peripheral membrane proteins important in many different roles, commonly as regulatory subunits of channel proteins and cell surface receptors. Their domains often undergo rearrangement, dissociation, or conformational changes when they interact with the membrane, resulting in the activation of their biological activity. In protein purification, peripheral membrane proteins are typically more water-soluble and much easier to isolate from the membrane than integral membrane proteins.

=== Addition to alkenes and alkynes === The Hg2+ center binds to alkenes, inducing the addition of hydroxide and alkoxide. For example, treatment of methyl acrylate with mercuric acetate in methanol gives an α-mercuri ester:

=== 13 June === The Ukrainian military claimed that its Third Special Operations Forces Regiment had destroyed a Russian R-416GM digital radio relay communication station, a truck-based system designed to improve the efficiency of radio relay units in the field, for the first time. Russia claimed to have shot down three drones over Yaroslavl Oblast and another over Vladimir Oblast. In Belgorod, the Governor claimed a drone damaged a car and injured two people. A Ukrainian court convicted a former executive of the Zaporizhzhia Nuclear Power Plant of collaborating with Russia and sentenced him to ten years' imprisonment. The G7 agreed to provide a $50 billion-loan derived from frozen Russian assets for military use by Ukraine during a summit in Italy that also saw the US and Ukraine sign a 10-year bilateral security deal. Canada pledged 2,000 decommissioned CRV7 “rocket motors”, armoured vehicles to be assembled in Kyiv, 29 Nanuk Remotely Controlled Weapon Stations and 130,000 rounds of ammunition to Ukraine.

Sources: en.wikipedia.org

Reference notes

=== Obsessive–compulsive disorder === In Canada, SSRIs are a first-line treatment of adult obsessive–compulsive disorder (OCD). In the UK, they are first-line treatment only with moderate to severe functional impairment and as second-line treatment for those with mild impairment, though, as of early 2019, this recommendation is being reviewed. SSRIs are more effective than placebo for reducing OCD symptoms and global severity in children and adolescents, and combining them with exposure therapy is probably more effective than using an SSRI alone.

Duterte has Buerger's disease, an inflammation of blood vessels, mostly in the limbs, and Barrett's esophagus, wherein esophageal cells are gradually replaced by gastrointestinal cells. He has denied rumors of throat cancer. Duterte admitted in December 2016 that he had been a user of the addictive opioid drug Fentanyl. He said that a doctor prescribed the drug to alleviate back pain and headaches, but that he would take more than he was prescribed. Duterte later denied that he was a drug addict, and a spokesman stated that he was not affected by side-effects of the drug, which include confusion, anxiety, and hallucinations. Duterte has boasted about his use of Viagra: "When I was young, I could do overnight, which is more expensive. When I got old, I could do short time only because I have such a short time left. After one erection, that's it. No more. Without Viagra, it's even more difficult." A psychological assessment of Duterte was commissioned by a doctor named Natividad Dayan during Duterte's marriage annulment to Elizabeth Zimmerman in July 1998. The result was that Duterte (then Davao City mayor) was found to have "antisocial narcissistic personality disorder", exemplified by "gross indifference, insensitivity and self-centeredness", and a "grandiose sense of self-entitlement and manipulative behaviors".

Alcoholic liver disease (ALD, or alcoholic cirrhosis) develops in 10–20% of individuals who drink heavily for a decade or more. Alcohol seems to injure the liver by blocking the normal metabolism of protein, fats, and carbohydrates. This injury happens through the formation of acetaldehyde from alcohol. Acetaldehyde is reactive and leads to the accumulation of other reactive products in the liver. People with ALD may also have concurrent alcoholic hepatitis. Associated symptoms are fever, hepatomegaly, jaundice, and anorexia. AST and ALT blood levels are both elevated, but at less than 300 IU/liter, with an AST:ALT ratio > 2.0, a value rarely seen in other liver diseases. In the United States, 40% of cirrhosis-related deaths are due to alcohol. In non-alcoholic fatty liver disease (NAFLD), fat builds up in the liver and eventually causes scar tissue. This type of disorder can be caused by obesity, diabetes, malnutrition, coronary artery disease, and steroids. Though similar in signs to alcoholic liver disease, no history of notable alcohol use is found. Blood tests and medical imaging are used to diagnose NAFLD and NASH, and sometimes a liver biopsy is needed. Chronic hepatitis C, an infection with the hepatitis C virus, causes inflammation of the liver and a variable grade of damage to the organ. Over several decades, this inflammation and damage can lead to cirrhosis. Among people with chronic hepatitis C, 20–30% develop cirrhosis. Cirrhosis caused by hepatitis C and alcoholic liver disease are the most common reasons for liver transplant.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.

Is AOD-9604 the same as human growth hormone?

No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.

Has AOD-9604 been approved for weight loss?

Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.

Is AOD-9604 approved for weight loss?

No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.

Network